MYD88 and Hepatic steatosis: The current study revealed that the specific deletion of MyD88 in HSCs/myofibroblasts attenuated DEN/HFD-induced hepatocarcinogenesis (Fig. 4), hepatic steatosis, cell proliferation, and lipogenesis (Fig. 5).